已收盤 11-20 16:00:00 美东时间
-0.017
-2.12%
11月18日,OS Therapies(OSTX)收涨9.42%,报0.74美元,成交额83.07万美元,市值3486.02万美元。 行情数据 • 开盘价:0...
11-18 08:33
OS Therapies Incorporated ( ($OSTX) ) just unveiled an announcement. OS Therapi...
11-13 02:27
11月11日,OS Therapies(OSTX)收跌3.27%,报0.89美元,成交额36.92万美元,市值4165.62万美元。 行情数据 • 开盘价:0...
11-11 08:25
11月4日,OS Therapies(OSTX)收涨0.87%,报1.16美元,成交额51.42万美元,市值5429.41万美元。 行情数据 • 开盘价:1....
11-04 08:18
10月28日,OS Therapies(OSTX)收涨1.65%,报1.23美元,成交额39.29万美元,市值5757.01万美元。 行情数据 • 开盘价:1...
10-28 07:20
10月20-22日上海黄浦江畔,2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势,更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-20 07:23
OS Therapies Incorporated ( ($OSTX) ) has issued an update. On October 11, 2026...
10-19 21:24
OS Therapies Inc. (NYSE:OSTX) announced a statistically significant three-year overall survival benefit for patients treated with OST-HER2 in its Phase 2b trial. The study evaluated the prevention or delay of recurrence in patients with fully resected, pulmonary metastatic osteosarcoma. Osteosarcoma...
10-07 01:19
OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced the appointment of Kerry Clem as Chief Commercial Officer (CCO) and Frank Knuettel II as Chief Financial Officer (CFO).
10-01 20:34
MHRA agreed that the use of comparable historical control data – derived from a systematic evaluation of all suitable available peer-reviewed literature by independent biostatistics advisors presented in its most recent Scientific Advice Meeting (SAM) - was appropriate in the orphan indication Preve...
09-15 19:50